Arrivent Biopharma Inc.
AVBP
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize our team's deep drug development experience to maximize the potential of our lead product candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as ne…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$169M
▼ -106.6% YoY
Op. Margin
–
ROIC
-41.07%
▲ +8.1pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$153M
▼ -128.7% YoY
Net Debt
-$393M
Net Cash Position
Cash & Equiv.
$393M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with AVBP
Held by ETFs
AVBP is in 30 US ETFs. The largest of them, with AVBP's weight in each:
Arrivent Biopharma (AVBP) in two numbers
Questions about Arrivent Biopharma
Does Arrivent Biopharma (AVBP) pay a dividend?
No. Arrivent Biopharma (AVBP) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 5 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in AVBP's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AVBP
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.